BTIG Research Forecasts Strong Price Appreciation for AtriCure (NASDAQ:ATRC) Stock

Key Points

• BTIG Research raised AtriCure’s price target to $63 from $55 while maintaining a “buy” rating, implying 12.88% upside from the prior close.
• Analyst sentiment remains generally positive, with seven Buy ratings and five Holds; the consensus rating is “Moderate Buy” with a $54.10 price target.
• AtriCure reported quarterly revenue of $153.6 million and EPS of $0.18, exceeding revenue expectations, while insiders have sold approximately $3.32 million in stock over the past 90 days.

AtriCure (NASDAQ:ATRC - Get Free Report) had its price target lifted by research analysts at BTIG Research from $55.00 to $63.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a "buy" rating on the medical device company's stock. BTIG Research's target price indicates a potential upside of 12.88% from the company's previous close.

Other analysts have also recently issued research reports about the stock. Zacks Research cut shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 24th. UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Needham & Company LLC increased their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a "buy" rating in a report on Wednesday, September 2nd. Piper Sandler raised their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. Finally, Freedom Capital cut AtriCure from a "strong-buy" rating to a "hold" rating in a report on Friday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $54.10.

AtriCure Stock Performance

Shares of NASDAQ ATRC opened at $55.81 on Monday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure has a 12 month low of $25.36 and a 12 month high of $61.70. The stock has a 50 day moving average of $50.96 and a 200-day moving average of $37.31. The company has a market capitalization of $2.84 billion, a P/E ratio of 265.77 and a beta of 1.24.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%. The business had revenue of $153.60 million for the quarter, compared to analysts' expectations of $151.80 million. During the same quarter in the prior year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts predict that AtriCure will post 0.29 EPS for the current year.

Insider Activity at AtriCure

In related news, insider Salvatore Privitera sold 4,519 shares of the firm's stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total transaction of $271,140.00. Following the transaction, the insider directly owned 142,745 shares of the company's stock, valued at approximately $8,564,700. This trade represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karen Prange sold 3,564 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director directly owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 74,868 shares of company stock valued at $3,317,897. 4.00% of the stock is currently owned by insiders.

Institutional Trading of AtriCure

A number of institutional investors have recently bought and sold shares of the business. Moody National Bank Trust Division bought a new position in AtriCure during the 3rd quarter worth $215,000. Tidal Investments LLC raised its holdings in AtriCure by 46.2% in the 2nd quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company's stock valued at $534,000 after acquiring an additional 6,034 shares in the last quarter. WINTON GROUP Ltd acquired a new position in AtriCure in the 2nd quarter valued at $1,002,000. Engineers Gate Manager LP lifted its position in shares of AtriCure by 12.3% during the 2nd quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company's stock valued at $1,348,000 after acquiring an additional 5,283 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of AtriCure during the 2nd quarter valued at $46,000. Institutional investors own 99.11% of the company's stock.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company's portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.